問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Division of General Surgery

Division of General Internal Medicine

Digestive System Department

Taipei Veterans General Hospital

更新時間：2023-09-19

陳仁熙Chen, Jen-Shi
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years 1 個月

Recruiting Trial

84Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳仁熙

List

205Cases

2010-11-01 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2006-01-01 - 2007-12-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Study ended3Sites

2012-03-01 - 2014-06-30

Phase II

A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination with Paclitaxel versus Paclitaxel alone in Patients with Metastatic, Gastric or Gastro-oesophageal Junction, Cancer who progress following First Line Therapy and are Ineligible for Treatment with trastuzumab by HER2 Status (SAGE)

  • Condition/Disease

    Gastric or Gastro-oesophageal Junction Cancer

  • Test Drug

    AZD8931

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

2011-12-01 - 2016-07-31

Phase II

A Randomised Open-Label Phase IIa Study to Assess the Efficacy and Safety of AZD4547 Monotherapy versus Paclitaxel in Patients with Advanced Gastric or Gastro-oesophageal Junction Cancer with FGFR2 Polysomy or Gene Amplification (Shine study)

  • Condition/Disease

    Advanced Gastric or Gastro-oesophageal Junction Cancer

  • Test Drug

    AZD4547

Participate Sites
7Sites

Terminated6Sites

Study ended1Sites

2015-07-01 - 2019-03-31

Phase I

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients with Advanced Solid Tumours

  • Condition/Disease

    Advanced Solid Tumours

  • Test Drug

    MEDI4736

Participate Sites
3Sites

Not yet recruiting3Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2014-06-01 - 2017-12-31

Phase III

A randomized, double-blinded, placebo controlled, multicentre phase III study to assess the efficacy and safety of olaparib (AZD2281) in combination with paclitaxel, compared to placebo in combination with paclitaxel, in Asian patients with advanced gastric cancer (including the gastro-oesophageal junction) who have progressed following first line therapy

  • Condition/Disease

    advanced gastric cancer

  • Test Drug

    Olaparib

Participate Sites
5Sites

Terminated5Sites

2018-08-15 - 2020-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2009-10-31 - 2012-10-20

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2019-03-01 - 2020-06-30

Phase II

A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3

  • Condition/Disease

    Solid Tumors

  • Test Drug

    Debio 1347

Participate Sites
7Sites

Terminated7Sites

2011-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

1 12 13 14 15 16 21
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB